Literature DB >> 35142651

Improving outcomes of women's cancer in India: A multidisciplinary multisectoral approach.

Sudeep Gupta1, Supriya Chopra2, Nita Nair3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 35142651      PMCID: PMC9131771          DOI: 10.4103/ijmr.ijmr_3335_21

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   5.274


× No keyword cloud information.
The life expectancy at birth in India was 32 years on the evening of our independence in 19471 which increased to 70 years in 20192. This is testimony to the remarkable progress made in many spheres of health and human development in the past seven and half decades in our society. Yet many challenges remain and indeed have become more manifest in this period. As any population ages, there is a gradual shift of disease burden from communicable to non-communicable diseases (NCD). In India, the current pattern is at that point of evolution, when communicable disease burden has not yet declined to low levels while NCD burden has already increased (and rising)3. Thus, our healthcare system is confronted with many simultaneous challenges and priorities. Cancer, by the very nature of this disease, is among the top health priorities in most countries and is rapidly attaining this status in India4. Cancers of the breast and ovary are among the most incident cancers in women and responsible for substantial morbidity and mortality. Both these diseases lend themselves to the early detection and have high cure rates when detected in early stages. It is a tragedy that a substantial proportion of patients in India continue to be diagnosed when they have already developed advanced stage disease4. Both diseases require multi-disciplinary management in modern hospitals which have requisite infrastructure and expertise. We continue to be deficient in adequate human resources and infrastructure to be able to care for all patients, especially in the public sector and outside major cities. The incidence of cervical cancer is declining throughout India in the past few decades5, for reasons that are not fully understood, but likely to be multifactorial. Unfortunately, this is accompanied by an increasing incidence of breast cancer, likely because of reproductive (hormonal) and other lifestyle-related risk factors5. These and other issues that are germane to breast and cervical cancer in India and similar countries, can be managed only with multisectoral intervention at the levels of health policy, public health expenditure, and capacity building in human resources, infrastructure and research. India has a long, if somewhat narrow, pedigree in basic, translational and clinical research in cancers, including those of the breast and cervix. The preceding decade has witnessed important, worldwide practice-defining clinical research in these two cancers from Indian institutions and groups678910. These efforts are praiseworthy but few and far between. The major weakness of the Indian system has been a lack of multi-institutional collaborative research groups, which could address important clinical and translational questions expeditiously. Such collaborative groupings are not conjured out of thin air, these require planning, passionate champions, collaborative spirit, and most importantly, dedicated funding. Some beginnings have been made and it is hoped that these will come of age, sooner rather than later. We have assembled a distinguished group of researchers, academicians and practitioners who have contributed to this special issue. A broad range of themes have been covered in the collection, in both breast and cervical cancers. These include early detection, diagnostic techniques, staging, biomarkers, surgery, radiotherapy and systemic therapy, palliative care, training and education, and controversies. Although these themes are universal, the authors have included data and evidence that may be especially relevant to India and other low-middle income countries. We believe that this is what makes this special issue of the Indian Journal of Medical Research (IJMR) unique and will enable it to frame the context in these cancers. We thank the authors for being considerate during the long duration of preparation of this issue, interrupted by the once-in-a-century pandemic. The issue could not have been published without the steadfast support of IJMR editorial staff, including the Editor-in-Chief. We are grateful to them for shepherding this issue. We do hope that the readers will enjoy reading the research, perspectives and wisdom contained in this issue, as much as we enjoyed assembling it.
  9 in total

1.  Health in India -- a futuristic scenario.

Authors:  A Ali
Journal:  Health Millions       Date:  1999 Jul-Aug

2.  Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.

Authors:  Sudeep Gupta; Amita Maheshwari; Pallavi Parab; Umesh Mahantshetty; Rohini Hawaldar; Supriya Sastri Chopra; Rajendra Kerkar; Reena Engineer; Hemant Tongaonkar; Jaya Ghosh; Seema Gulia; Neha Kumar; T Surappa Shylasree; Renuka Gawade; Yogesh Kembhavi; Madhuri Gaikar; Santosh Menon; Meenakshi Thakur; Shyam Shrivastava; Rajendra Badwe
Journal:  J Clin Oncol       Date:  2018-02-12       Impact factor: 44.544

3.  Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial.

Authors:  Rajendra Badwe; Rohini Hawaldar; Vani Parmar; Mandar Nadkarni; Tanuja Shet; Sangeeta Desai; Sudeep Gupta; Rakesh Jalali; Vaibhav Vanmali; Rajesh Dikshit; Indraneel Mittra
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Convergence of non-communicable and infectious diseases in low- and middle-income countries.

Authors:  Justin V Remais; Guang Zeng; Guangwei Li; Lulu Tian; Michael M Engelgau
Journal:  Int J Epidemiol       Date:  2012-10-13       Impact factor: 7.196

6.  Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

Authors:  Rajendra Badwe; Rohini Hawaldar; Nita Nair; Rucha Kaushik; Vani Parmar; Shabina Siddique; Ashwini Budrukkar; Indraneel Mittra; Sudeep Gupta
Journal:  Lancet Oncol       Date:  2015-09-09       Impact factor: 41.316

7.  Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.

Authors:  Supriya Chopra; Sudeep Gupta; Sadhana Kannan; Tapas Dora; Reena Engineer; Akshay Mangaj; Amita Maheshwari; T Surappa Shylasree; Jaya Ghosh; Siji N Paul; Reena Phurailatpam; Mayuri Charnalia; Mitali Alone; Jamema Swamidas; Umesh Mahantshetty; Kedar Deodhar; Rajendra Kerkar; Shyam K Shrivastava
Journal:  J Clin Oncol       Date:  2021-09-10       Impact factor: 50.717

8.  Global burden of cancer.

Authors:  Xiaomei Ma; Herbert Yu
Journal:  Yale J Biol Med       Date:  2006-12

9.  A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery.

Authors:  Dinesh Chandra Doval; Selvi Radhakrishna; Rupal Tripathi; Renu Iyer Kashinath; Vineet Talwar; Ullas Batra; Naga Amulya Mullapudi; Kapil Kumar; Ajay Kumar Dewan; Harit Chaturvedi; Juhi Tayal; Anurag Mehta; Sudeep Gupta; Ramesh B V Nimmagadda
Journal:  Sci Rep       Date:  2020-04-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.